The first evidence for SLFN11 expression as an independent prognostic factor for patients with esophageal cancer after chemoradiotherapy

Table 3 Relationship between SLFN11 expression level and clinicopathological variables

Variable		SLFN-11 expression		P value
		Low	High
		n (%)	n (%)
Gender	Male	32 (52.5)	29 (47.5)	0.345
Gender	Female	4 (33.3)	8 (66.7)	0.345
Age	< 65	9 (34.6)	17 (65.4)	0.062
Age	≥ 65	27 (57.4)	20 (42.6)	0.062
Number of pre-dCRT biopsy specimens including tumor tissue	1	5 (45.5)	6 (54.5)	0.781
Number of pre-dCRT biopsy specimens including tumor tissue	≥ 2	31 (50.0)	31 (50.0)	0.781
Histological type	Differentiated	33 (51.6)	31 (48.4)	0.725
Histological type	Un-differentiated	3 (33.3)	6 (66.7)	0.725
Depth of invasion	cT1b or T2	12 (50.0)	12 (50.0)	0.935
Depth of invasion	cT3 - T4b	24 (49.0)	25 (51.0)	0.935
Tumor size	< 5 cm	17 (48.6)	18 (51.4)	0.903
Tumor size	≥ 5 cm	19 (50.0)	19 (50.0)	0.903
Lymphatic metastasis	cN0	11 (45.8)	13 (54.2)	0.677
(regional lymph node)	cN1 - N3	25 (51.0)	24 (49.0)	0.677
Distant metastasis	cM0	32 (50.8)	31 (49.2)	0.736
(distant lymph node)	cM1 -lym	4 (40.0)	6 (60.0)	0.736

Abbreviations: CI confidence interval, cT1b tumor invasion to the submucosa, cT2 tumor invasion to the muscularis propria, cT3 tumor invasion to the adventitia, cT4b tumor invades adjacent structures, such as the aorta, vertebral body, or trachea, cN0 no regional lymph node metastasis, cN1 metastasis in 1–2 regional lymph nodes, cN3 metastasis in 7 or more regional lymph nodes, cM0 no distant metastasis, cM1-lym distant lymph node metastasis, dCRT definitive chemoradiotherapy

ISSN: 1471-2407